Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 5/20 | 0.52 |
| ▸ | SYK | P43405 | 6/20 | 0.51 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.44 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.43 |
| ▸ | BMX | P51813 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | STK17B | O94768 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3494248 | 0.88 | BRD4 (0.58) | ULK1SYKPRKCQBRD4MAPT | |
| SCHEMBL3496761 | 0.87 | ULK1 (0.53) | ULK1SYKPRKCQBRD4STK17A | |
| SCHEMBL3494882 | 0.87 | SYK (0.62) | ULK1SYKPRKCQBRD4BMX | |
| SCHEMBL3496445 | 0.84 | ULK1 (0.51) | ULK1SYKPRKCQBRD4STK17A | |
| SCHEMBL3495134 | 0.84 | ULK1 (0.51) | ULK1SYKPRKCQBRD4STK17A | |
| SCHEMBL3496386 | 0.84 | SYK (0.58) | ULK1SYKPRKCQBMXBTK | |
| SCHEMBL3495757 | 0.83 | ULK1 (0.49) | ULK1SYKPRKCQBRD4STK17A | |
| SCHEMBL3496305 | 0.81 | PRKCQ (0.60) | ULK1SYKPRKCQBRD4ULK2 | |
| SCHEMBL3494055 | 0.81 | ULK1 (0.56) | ULK1SYKPRKCQBRD4STK17A | |
| SCHEMBL3647914 | 0.81 | PRKCQ (0.44) | ULK1PRKCQBRD4ULK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | claimed |
| EP-2183225-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | claimed |
| WO-2009012421-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-22 | — | — | WO | claimed |
| US-8993585-B2 | Cyclic amine substituted pyrimidinediamines as PKC inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
| EP-2183225-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009012421-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | PRKCH, PKD2, PRKCQ | ULK1 832/4885SYK 460/4885PRKCQ 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.